Search Within

Myeloma

Formats
  1. Meeting Abstract (557)
  2. Journal Article (368)
  3. Review (37)
  4. Research Letter (21)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (7)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (1016)
  2. Department of Medicine (1016)
  3. Hematologic Malignancies, Division of (1016)
  4. Hematologic Malignancies Research (669)
  5. Survivorship Research (374)
  6. Sloan Kettering Institute Postdocs (306)

More Groups

People
  1. Alexander Lesokhin (381)
  2. Hani Hassoun (339)
  3. Carl Landgren (336)
  4. Sham Mailankody (297)
  5. Malin Hultcrantz (274)
  6. Heather Landau (249)

More People

Years
  1. 2025 (28)
  2. 2024 (82)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (317)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (86)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (24)

More Publications

Publishers
  1. American Society of Hematology (340)
  2. Elsevier Inc. (160)
  3. American Society of Clinical Oncology (88)
  4. Nature Publishing Group (87)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (1016)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of carfilzomib-lenalidomide-dexamethasone (KRd) in newly diagnosed multiple myeloma: Pooled analysis of 4 single-arm studies
    Meeting Abstract

    Landgren, O.; Attal, M.; Kazandjian, D.; Roussel, M.; Jasielec, J. K.; Dytfeld, D.; Anderson, A.; Kervin, T.; Iskander, K.; Mezzi, K.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase 1 first-in-human study of the anti-CD38 dimeric fusion protein TAK-169 for the treatment of patients (pts) with relapsed or refractory multiple myeloma (RRMM) who are proteasome inhibitor (PI)- and immunomodulatory drug (IMiD)-refractory, including pts relapsed/refractory (R/R) or naïve to daratumumab (dara)
    Meeting Abstract

    Kumar, S. K.; Cornell, R. F.; Landgren, O.; Ailawadhi, S.; Higgins, J. P.; Willert, E. K.; Waltzman, R.; Lin, J.; Zhang, Y.; Lublinsky, A. R.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster
    Meeting Abstract

    Jasra, S.; Giricz, O.; Zeig-Owens, R.; Goldfarb, D.; Barreto-Galvez, A.; Pradhan, K.; Chen, J.; Choudhary, G. S.; Aluri, S.; Bhagat, T. D.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Hematological count recovery in patients undergoing treatment with chimeric antigen receptor T cells (CAR T)
    Meeting Abstract

    Jain, T.; Knezevic, A.; Pennisi, M.; Ruiz, J. D.; Devlin, S. M.; Maloy, M. A.; Halton, E.; Diamonte, C.; Scordo, M.; Sauter, C. S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Plasma cell myeloma residual disease quantitation using a next-generation sequencing-based IGH clonal rearrangement assay with the aid of a "spike-in" clonal sequence
    Meeting Abstract

    Ho, C.; Syed, M.; Yu, W.; Petrova-Drus, K.; Yao, J. J.; Moung, C.; Chang, J.; Benhamida, J.; Vanderbilt, C.; Roshal, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Using current clinical markers to define high risk smoldering multiple myeloma: Agree to disagree
    Meeting Abstract

    Hill, E.; Korde, N.; Mailankody, S.; Morrison, C.; Dew, A.; Albert, J. H.; Graap, K.; Maura, F.; Landgren, O.; Kazandjian, D.
    Blood (2019)

    Fulltext@MSK | Save
  • Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow based flow cytometry for tracking measurable residual disease (MRD) in patients with multiple myeloma
    Meeting Abstract

    Eveillard, M.; Rustad, E. H.; Roshal, M.; Zhang, Y.; Ciardiello, A. K.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Smith, E. L.; Lesokhin, A. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • FDA analysis: Impact of body mass index (BMI) on outcomes in relapsed-refractory multiple myeloma
    Meeting Abstract

    Ershler, R.; Kanapuru, B.; Gong, Y.; Shah, U. A.; Mailankody, S.; Landgren, O.; Theoret, M.; Gormley, N. J.; Farrell, A. T.; Pazdur, R.
    Blood (2019)

    Fulltext@MSK | Save
  • MALDI-TOF mass spectrometry in serum for the follow-up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
    Meeting Abstract

    Eveillard, M.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Smith, E. L.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Korde, N.; Landgren, O.; more...
    Blood (2019)

    Fulltext@MSK | Save